Skip to main content

Table 1 Demographic and patient characteristics in treatment groups and controls

From: Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment

  RA without DMARD
(n = 50)
RA with MTX
(n = 10)
pSS without DMARD (n = 15) Controls
(n = 49)
Age, median (range) years 66.9 (35–87) 67.4 (39–79) 62.3 (25–89) 57.2 (17–85)
Sex (% female) 78.0 70.0 87.0 63.3
Disease duration, mean (range) years 5.6 (0–36) 13.1 (2–40) 7.0 (0–23)
CRP, median (range) mg/L 7 (0–78) 3 (0–11) 1.7 (0.7–38)
ESR, median (range) mm/h 21 (4–71) 16 (5–42) 12 (7–66)
RF positive, % 78 80 43
ACPA positive, % 69 70 8
ANA positive, % 73
Anti-ENA positive, % 73
Anti-SSA (anti-Ro) positive, % 67
Anti-SSB (anti-La) positive, % 40
Prednisolone, % 58 0 13 0
Dose, median (range) mg/day 5 (0–15) 0 0 (0–10)
Previous PPV23, n (%): 1 (2) 0 0 3 (6)
  1. DMARD Disease modifying anti rheumatic drugs, RA Rheumatoid arthritis, pSS primary Sjögren’s syndrome, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, ACPA Antibodies against citrullinated peptides, ANA Antinuclear antibodies, Anti-ENA Antibodies against extractable nuclear antigens, Anti-SSA (anti-Ro) Anti-Sjögren’s-syndrome-related antigen A, Anti-SSB (anti-La) Anti-Sjögren’s-syndrome-related antigen B, RF Rheumatoid factor